• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    108.18 -1.00 (-0.92%)
    Official Closing Price Updated: 7:00 PM EST, Jan 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,491,368
    Open 109.09
    Bid (Size) 107.70 (100)
    Ask (Size) 108.35 (1,500)
    Prev. Close 109.18
    Today's Range 107.21 - 109.09
    52wk Range 73.31 - 112.90
    Shares Outstanding 2,531,374,696
    Dividend Yield 3.14%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
    Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
    Via The Motley Fool
    Topics ETFs Intellectual Property World Trade
    News headline image
    2 Dirt Cheap Stocks to Buy With $200 Right Now ↗
    These healthcare leaders seem attractive right now. 
    Via The Motley Fool
    Topics Artificial Intelligence

    Performance

    YTD
    +1.6%
    +1.6%
    1 Month
    +1.3%
    +1.3%
    3 Month
    +22.9%
    +22.9%
    6 Month
    +28.7%
    +28.7%
    1 Year
    +13.2%
    +13.2%

    More News

    Read More
    Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock ↗
    Via Chartmill
    News headline image
    Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
    Via The Motley Fool
    News headline image
    2 Soaring Stocks to Hold for the Next 20 Years ↗
    Via The Motley Fool
    Topics Intellectual Property World Trade
    MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
    Via Stocktwits
    ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
    Via MarketMinute
    Topics Artificial Intelligence Bankruptcy Economy
    News headline image
    I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
    Via MarketMinute
    Topics Earnings Economy Intellectual Property
    News headline image
    Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm
    Via StockStory
    Topics Economy Stocks
    News headline image
    Why Moderna Stock Surged Today ↗
    Via The Motley Fool
    News headline image
    Merck Shares Rise On $30M Funding From CEPI To Develop Affordable Ebola Vaccine ↗
    Via Stocktwits
    Topics Workforce
    News headline image
    Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗
    Via Stocktwits
    News headline image
    Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
    Via Stocktwits
    News headline image
    GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
    Via ACCESS Newswire
    News headline image
    3 “Forever Stocks” to Hold When the Market Won’t Sit Still ↗
    Via MarketBeat
    News headline image
    The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature
    Via Finterra
    Topics Artificial Intelligence Bankruptcy Economy
    News headline image
    3 Profitable Stocks to Consider Right Now
    Via StockStory
    News headline image
    The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
    Via Finterra
    Topics Initial Public Offering Intellectual Property Lawsuit
    News headline image
    2 Unpopular Stocks That Should Get More Attention and 1 We Brush Off
    Via StockStory
    News headline image
    The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
    Via MarketMinute
    Topics Economy Intellectual Property

    Frequently Asked Questions

    Is Merck & Co publicly traded?
    Yes, Merck & Co is publicly traded.
    What exchange does Merck & Co trade on?
    Merck & Co trades on the New York Stock Exchange
    What is the ticker symbol for Merck & Co?
    The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
    What is the current price of Merck & Co?
    The current price of Merck & Co is 108.18
    When was Merck & Co last traded?
    The last trade of Merck & Co was at 01/23/26 07:00 PM ET
    What is the market capitalization of Merck & Co?
    The market capitalization of Merck & Co is 273.84B
    How many shares of Merck & Co are outstanding?
    Merck & Co has 274B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.